表紙
市場調查報告書

缺血性中風:市場聚光燈

Market Spotlight: Ischemic Stroke

出版商 Datamonitor Healthcare 商品編碼 955901
出版日期 內容資訊 英文 46 Pages
商品交期: 最快1-2個工作天內
價格
缺血性中風:市場聚光燈 Market Spotlight: Ischemic Stroke
出版日期: 2020年07月31日內容資訊: 英文 46 Pages
簡介

Datamonitor Healthcare ,估算在2018年中在世界約發生8230萬件缺血性中風,其數預計至2027年增加到8800萬件。

本報告提供缺血性中風的主要的上市藥、開發平台藥物,近幾年的動向和分析師的見解,臨床試驗,成功的可能性,不久將來的動向、規定趨勢,專利資訊,授權、資產取得交易等相關分析。

目錄

內容

概要

要點

疾病的背景

  • 疾病定義
  • 症狀
  • 危險因素
  • 診斷

治療

  • 缺血性中風的急性期治療
  • 長期治療
  • 緩和照護

流行病學

成藥

開發平台藥物

最近的活動和分析師的見解

  • DM199(2020年5月13日)
  • NA-1(2020年2月20日)
  • Fetzima(2019年6月25日)
  • Solitaire FR(2019年4月30日)
  • ReN001(2019年4月9日)
  • Clotbust ER(2019年3月22日)
  • SB623(2019年1月29日)

主要的今後的活動

主要的法規活動

  • Medtronic,在中風患者的置入式監測相關英國國立醫療技術評估機構決策中勝利;Biotronik 及 Abbott 敗北

成功的概率

授權與資產取得交易

  • 大日本住友製藥, 解除跟SanBio的中風細胞治療相關聯盟契約

臨床試驗情勢

  • 贊助商:各狀態
  • 贊助商:各階段
  • 最近的事件

參考文件

  • 藥方資訊

附錄

圖的清單

表格的清單

目錄
Product Code: DMKC0219264

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 88.0 million prevalent cases by 2027.

The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.

The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.

High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Trans Sodium Crocetinate and TMS-007, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected PDUFA date for Brilinta.

The overall likelihood of approval of a Phase I stroke asset is 0.8%, and the average probability a drug advances from Phase III is 9.1%. Drugs, on average, take 6.8 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I-II, and 30% in Phase III-IV.

The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 21 trials.

Roche leads industry sponsors with the highest overall number of clinical trials for stroke, followed by Boehringer Ingelheim and Daiichi Sankyo.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Acute treatment of ischemic stroke
  • Long-term treatments
  • Palliative care

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • DM199 for Ischemic Stroke (May 13, 2020)
  • NA-1 for Ischemic Stroke (February 20, 2020)
  • Fetzima for Ischemic Stroke (June 25, 2019)
  • Solitaire FR for Ischemic Stroke (April 30, 2019)
  • ReN001 for Ischemic Stroke (April 9, 2019)
  • Clotbust ER for Ischemic Stroke (March 22, 2019)
  • SB623 for Ischemic Stroke (January 29, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Medtronic Wins In England's NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of ischemic stroke, 2018-27
  • Figure 2: Overview of pipeline drugs for ischemic stroke in the US
  • Figure 3: Pipeline drugs for ischemic stroke, by company
  • Figure 4: Pipeline drugs for ischemic stroke, by drug type
  • Figure 5: Pipeline drugs for ischemic stroke, by classification
  • Figure 6: DM199 for Ischemic Stroke (May 13, 2020): Phase II - ReMEDy
  • Figure 7: NA-1 for Ischemic Stroke (February 20, 2020): Phase III - ESCAPE-NA1
  • Figure 8: Clotbust ER for Ischemic Stroke (March 22, 2019): Phase III - CLOTBUST-ER (US)
  • Figure 9: SB623 for Ischemic Stroke (January 29, 2019): Phase IIb - ACTIsSIMA
  • Figure 10: Key upcoming events in ischemic stroke
  • Figure 11: Probability of success in the ischemic stroke pipeline
  • Figure 12: Clinical trials in stroke
  • Figure 13: Top 10 drugs for clinical trials in stroke
  • Figure 14: Top 10 companies for clinical trials in stroke
  • Figure 15: Trial locations in stroke
  • Figure 16: Stroke trials status
  • Figure 17: Stroke trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of ischemic stroke, 2018-27
  • Table 2: Marketed drugs for ischemic stroke
  • Table 3: Pipeline drugs for ischemic stroke in the US
  • Table 4: DM199 for Ischemic Stroke (May 13, 2020)
  • Table 5: NA-1 for Ischemic Stroke (February 20, 2020)
  • Table 6: Fetzima for Ischemic Stroke (June 25, 2019)
  • Table 7: Solitaire FR for Ischemic Stroke (April 30, 2019)
  • Table 8: ReN001 for Ischemic Stroke (April 9, 2019)
  • Table 9: Clotbust ER for Ischemic Stroke (March 22, 2019)
  • Table 10: SB623 for Ischemic Stroke (January 29, 2019)